Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled …
Background Risankizumab is a humanised IgG1 monoclonal antibody that binds to the p19
subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation. We …
subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation. We …
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus
…, N Basset-Seguin, R Bissonnette, P Foley… - Journal of the American …, 2007 - Elsevier
Topical photodynamic therapy (PDT) is used to treat nonmelanoma skin cancers, such as
actinic keratoses, Bowen's disease, and basal cell carcinoma (superficial and nodular). This …
actinic keratoses, Bowen's disease, and basal cell carcinoma (superficial and nodular). This …
The effect of regular sunscreen use on vitamin D levels in an Australian population: results of a randomized controlled trial
R Marks, PA Foley, D Jolley, KR Knight… - Archives of …, 1995 - jamanetwork.com
Background and Design: Studies published have suggested a possibility that regular use of
sunscreen to prevent skin cancer may put the population, particularly elderly people, at risk …
sunscreen to prevent skin cancer may put the population, particularly elderly people, at risk …
Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study
…, MM Okun, EP Prens, R Gniadecki, PA Foley… - Journal of the American …, 2019 - Elsevier
Background The optimal long-term dosing strategy for adalimumab (ADA) in hidradenitis
suppurativa/acne inversa (HS) was evaluated by pooling the results of the PIONEER phase 3 …
suppurativa/acne inversa (HS) was evaluated by pooling the results of the PIONEER phase 3 …
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year …
Background Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks signalling
of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic …
of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic …
[HTML][HTML] Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to …
K Reich, AW Armstrong, P Foley, M Song… - Journal of the american …, 2017 - Elsevier
Background Phase II data suggested that guselkumab, an anti-interleukin-23 monoclonal
antibody, was efficacious in psoriasis. Objective We sought to assess efficacy and safety of …
antibody, was efficacious in psoriasis. Objective We sought to assess efficacy and safety of …
Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis
The prevalence, associations, and natural history of pain in multiple sclerosis (MS) are poorly
understood. The objective of this work was to study the prevalence of pain syndromes in …
understood. The objective of this work was to study the prevalence of pain syndromes in …
Incidence of non-melanocytic skin cancer treated in Australia
GG Giles, R Marks, P Foley - Br Med J (Clin Res Ed), 1988 - bmj.com
In 1985, as part of a national random household omnibus survey by a market research
company, 30 976 Australians (mostly of European origin) were asked whether they had ever …
company, 30 976 Australians (mostly of European origin) were asked whether they had ever …
[HTML][HTML] Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis
…, A Morita, M Gooderham, P Foley… - … England Journal of …, 2018 - Mass Medical Soc
Background Tyrosine kinase 2 (TYK2) signaling pathways, which mediate cytokine signaling,
are implicated in the pathophysiology of psoriasis. Selective inhibitors of TYK2 may be …
are implicated in the pathophysiology of psoriasis. Selective inhibitors of TYK2 may be …
[HTML][HTML] Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double …
Background Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, inhibits
cytokine signaling in psoriasis pathogenesis. Objective The objective of this study was to …
cytokine signaling in psoriasis pathogenesis. Objective The objective of this study was to …